AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2155697
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy (four cycles) after radiotherapy
Trial: 2155697
Drug: Initial chemotherapy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial chemotherapy (vindesine-cisplatin)
Trial: 2155697
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (chemotherapy followed by radiotherapy)
Trial: 31868149
Drug: Nanocurcumin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocurcumin (40 mg capsule every 12 hours for six weeks)
Trial: 31868149
Drug: Placebo (similar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (similar components of nanomicelle curcumin capsules without curcumin)
Trial: 27533333
Drug: 24% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% sucrose solution administered orally 2 minutes prior to PIV catheter insertion
Trial: 27533333
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution administered orally 2 minutes prior to PIV catheter insertion
Trial: 23111980
Drug: Remogliflozin etabonate
RxNorm normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remogliflozin etabonate (RE) 100 mg administered to the mid‐small intestine
Trial: 23111980
Drug: Remogliflozin etabonate
RxNorm normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remogliflozin etabonate (RE) 100 mg administered to the large intestine
Trial: 23111980
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of the IR tablet of RE
Trial: 17086074
Drug: Tinnitus-coping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinnitus-coping therapy (TCT) with TCI provision
Trial: 17086074
Drug: Tinnitus-coping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinnitus-coping therapy (TCT) without TCI devices
Trial: 17086074
Drug: Waiting-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list control group (no treatment for 12 months)
Trial: 9863541
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg nocte
Trial: 8574712
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant EGF administered subcutaneously
Trial: 313873
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) in combination with intramuscularly administered C. parvum
Trial: 31364896
Drug: Augmented biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented biofeedback training and physical therapy (Group C)
Trial: 31364896
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (Group A)
Trial: 26837463
Drug: 40-mg oral
RxNorm normalized name: estradiol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-mg oral atomoxetine
Trial: 23469599
Drug: Yiqi Fumai
RxNorm normalized name: Aspergillus fumigatus allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Fumai Injection (YFI) alone, 2.6 g YFI in 250 mL normal saline, once daily for 15 days
Trial: 23469599
Drug: Hydroxychloroquine sulfate
RxNorm normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine sulfate alone, 0.2 g twice daily for 15 days
Trial: 23469599
Drug: Yiqi Fumai
RxNorm normalized name: Aspergillus fumigatus allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Fumai Injection (YFI) combined with hydroxychloroquine sulfate, same dosages as Groups A and B for 15 days
Trial: 20203451
Drug: Multiple risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple risk factor intervention strategy based on single‐pill amlodipine besylate/atorvastatin calcium
Trial: 18790313
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy-based intervention delivered by trained primary health workers
Trial: 15863377
Drug: Tamoxifen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (10 mg per day for 24 weeks)
Trial: 15863377
Drug: Bicalutamide alone
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicalutamide alone (150 mg per day)
Trial: 12002672
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Ginkgo biloba extract twice daily for 7 days
Trial: 12002672
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg Ginkgo biloba extract once daily for 7 days
Trial: 8983868
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (19 amino acids, 240 kJ/h)
Trial: 8983868
Drug: Control (isovolumic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (isovolumic infusions of nutrient-free saline solution)
Trial: 1744992
Drug: Sulphadimidine 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphadimidine 250 mg
Trial: 1744992
Drug: Sulphadimidine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphadimidine 500 mg
Trial: 1744992
Drug: Sulphadimidine 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphadimidine 750 mg
Trial: 1744992
Drug: Sulphadimidine 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphadimidine 1000 mg
Trial: 1744992
Drug: Initial oral
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial oral dose of 750 mg
Trial: 31377284
Drug: Teprotumumab (fully
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teprotumumab (fully human monoclonal IGF‐1R antagonist antibody)
Trial: 30382734
Drug: Juvenile Justice
RxNorm normalized name: Justicia spicigera leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juvenile Justice Anger Management (JJAM) Treatment
Trial: 17040483
Drug: Immediate periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate periodontal therapy (early treatment)
Trial: 17040483
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care followed by periodontal therapy (deferred treatment)
Trial: 16232154
Drug: MIG-99 (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIG-99 (6.25 mg t.i.d.)
Trial: 7780891
Drug: Ofloxacin drops
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin drops (0.3% solution, 10 drops)
Trial: 7780891
Drug: Tobramycin drops
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin drops (0.3% solution, 10 drops) with erythromycin ointment post-surgery
Trial: 21504616
Drug: Fluconazole in
RxNorm normalized name: fluconazole Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole in situ gels (0.5% w/v) for 14 days
Trial: 21504616
Drug: Fluconazole tablets
RxNorm normalized name: Fluconazole Tablets
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole tablets (100 mg/day) for 14 days
Trial: 18291275
Drug: Intraosseous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous injection using the IntraFlow system
Trial: 9021813
Drug: Propacetamol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol (30 mg/kg)
Trial: 9021813
Drug: Propacetamol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol (15 mg/kg)
Trial: 29379114
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation (CR) plus a weekly goal-setting group
Trial: 22939029
Drug: Compensatory cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compensatory cognitive training + standard pharmacotherapy
Trial: 19165785
Drug: Scaffolds with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaffolds with mTGase treatment
Trial: 15955154
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate or budesonide, initial dose of 300, 400 or 600 microg/day, reduced to maintenance level of 200, 300 or 400 microg/day after stabilization.
Trial: 11992983
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy for eight weeks
Trial: 8109759
Drug: mivacurium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mivacurium 0.2 mg/kg, IV (Group II)
Trial: 8109759
Drug: succinylcholine 1
RxNorm normalized name: Succinylcholine 124 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: succinylcholine 1 mg/kg, IV (Group I)
Trial: 8109759
Drug: mivacurium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mivacurium 0.2 mg/kg, IV (Group III)
Trial: 8109759
Drug: neostigmine 2.5
RxNorm normalized name: neostigmine 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neostigmine 2.5 mg and glycopyrrolate 0.5 mg, IV (Group III)
Trial: 23550856
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 40 mg, repeated after 4 h as needed
Trial: 23550856
Drug: Misoprostol 25
RxNorm normalized name: Misoprostol 25 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 25 μg, repeated after 4 h as needed
Trial: 21334136
Drug: PSA <3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA <3.0 ng/ml screening
Trial: 15562900
Drug: Amoxicillin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (10 days)
Trial: 9778071
Drug: Fosinopril 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril 5 to 20 mg every day
Trial: 9778071
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 to 20 mg every day
Trial: 7609497
Drug: Lacidipine 4
RxNorm normalized name: lacidipine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine 4 mg once daily for 1 week
Trial: 7609497
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg twice daily for 1 week
Trial: 31308627
Drug: Pregabalin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150 mg) and celecoxib (200 mg) 2 hrs before surgery
Trial: 10374092
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative treatment
Trial: 18158076
Drug: G +
RxNorm normalized name: Citracal 250 mg + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G + Met
Trial: 17178796
Drug: Entecavir (ETV)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir (ETV) 1.0 mg
Trial: 11786772
Drug: Ropivacaine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (40 ml of 0.75 percent)
Trial: 7986518
Drug: Sublingual clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual clonidine 0.3 mg
Trial: 7986518
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 0.3 mg
Trial: 2493098
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg mitomycin C with 200,000 units hyaluronidase
Trial: 2493098
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg mitomycin C alone
Trial: 30300020
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) therapy, 4 sessions of 29J/cm2 at 3 weekly intervals
Trial: 30300020
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel sheet (SGS), applied over the other half of the scar and changed at 3 weekly intervals
Trial: 29364096
Drug: Levofloxacin containing
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin containing sequential therapy with bismuth
Trial: 29364096
Drug: Levofloxacin containing
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin containing sequential therapy
Trial: 2566778
Drug: Ticlopidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250 mg twice daily)
Trial: 23099620
Drug: Ticlopidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250 mg twice daily) + Itraconazole (200 mg once daily)
Trial: 20225473
Drug: Collagenase solution
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Collagenase solution
Trial: 20225473
Drug: Esterase solution
RxNorm normalized name: cocaine esterase
DrugBank: COCAINE ESTERASE (RBP-8000) (DB19225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esterase solution
Trial: 20225473
Drug: Phosphate buffer
RxNorm normalized name: PHOSPHATE BUFFERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffer solution
Trial: 10657767
Drug: Broad spectrum
RxNorm normalized name: Broad spectrum penicillin
DrugBank: Octinoxate (DB09496)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Broad spectrum herbal therapy ointment (BSHT) at 1% v/v
Trial: 8478306
Drug: Dirithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dirithromycin (500 mg once daily for 5-7 days)
Trial: 8478306
Drug: Miocamycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miocamycin (600 mg twice daily for 5-7 days)
Trial: 3021498
Drug: Nedocromil sodium,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium, 4 mg four times daily
Trial: 29996476
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (400 mg of magnesium oxide daily)
Trial: 27613505
Drug: Varenicline (0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (0.5mg BID × 5 doses)
Trial: 12270988
Drug: Mupirocin (thrice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mupirocin (thrice-weekly application)
Trial: 12270988
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no ointment)
Trial: 2195734
Drug: cyclosporin (Cs)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclosporin (Cs) treatment for one year
Trial: 2195734
Drug: cyclosporin (Cs)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclosporin (Cs) treatment for three months
Trial: 2195734
Drug: cyclosporin (Cs)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclosporin (Cs) treatment for twelve months
Trial: 2195734
Drug: cyclosporin (Cs)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclosporin (Cs) treatment
Trial: 154624
Drug: Arecoline (cholinergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arecoline (cholinergic agonist)
Trial: 31195828
Drug: 1-day Acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day Acceptance and Commitment Therapy workshop
Trial: 28158981
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medication availability
Trial: 26232911
Drug: 250 g
RxNorm normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 g of low-fat lamb per day
Trial: 26232911
Drug: 250 g
RxNorm normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 g of high-fat lamb per day
Trial: 23957603
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (Ecologic 825, Winclove, Amsterdam, the Netherlands) for 8 weeks after 4 weeks of antibiotics
Trial: 23957603
Drug: Antibiotics or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics or probiotics
Trial: 15863861
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.1% adapalene gel + 5% benzoyl peroxide
Trial: 7447218
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of methylprednisolone, intravenously, once a month for 6 months
Trial: 24608310
Drug: 4-L PEG
RxNorm normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-L PEG solution
Trial: 17716288
Drug: Lipo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipo Cream
Trial: 17716288
Drug: Lipo Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipo Ointment
Trial: 11756949
Drug: Tacrolimus (FK506)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (FK506) 0.1% ointment
Trial: 956798
Drug: Therapist self-reported
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist self-reported behavioral arousal during therapy
Trial: 956798
Drug: Physiological activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological activation during therapy (measured by electromyogram, heart rate, blood pressure, skin conductance)
Trial: 26608727
Drug: Direct access
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct access to low-dose computed tomography (LDCT) from primary care combined with a 1 h lung cancer update meeting.
Trial: 22761006
Drug: Trans-dermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trans-dermal nicotine patches and cognitive behavioral therapy (Group 1)
Trial: 22761006
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy alone (Group 2)
Trial: 16801465
Drug: Trandolapril (target,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (target, 4 mg/d)
Trial: 12732391
Drug: Unopposed 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unopposed 17beta-estradiol administered for a 2-year treatment period
Trial: 10819344
Drug: Cefpodoxime-proxetil, 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpodoxime-proxetil, 8 mg/kg/day in two divided doses for 5 days followed by 5 days of placebo
Trial: 10819344
Drug: Cefpodoxime-proxetil, 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpodoxime-proxetil, 8 mg/kg/day in two divided doses for 10 days
Trial: 10641772
Drug: CAPD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPD treatment
Trial: 1797696
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg carteolol/day
Trial: 6683554
Drug: Bifonazole cream
RxNorm normalized name: bifonazole
DrugBank: Bifonazole (DB04794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifonazole cream 1%, solution 1%, gel 1%, and powder 1% administered once daily for 2 or 3 weeks
Trial: 29228436
Drug: Atomized inhalation
RxNorm normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomized inhalation of ipratropium bromide and budesonide suspension, oxygen flow 3-5 L/min, 15-20 min/time, twice a day for 1 week
Trial: 29228436
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received routine treatment including saline through a ventilator mask
Trial: 29228436
Drug: Atomized inhalation
RxNorm normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomized inhalation of ipratropium bromide and budesonide suspension
Trial: 26435087
Drug: InterX5000 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: InterX5000 treatment
Trial: 24354496
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg/day for 4 weeks
Trial: 24354496
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg/day for 4 weeks
Trial: 17890171
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure lowering with perindopril/indapamide combination